Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miso Kim

Showing results (101-110 of 184) with videos related to

Pageof 19
Sort By:
Cytotherapy|April 24, 2019
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitorsHa-Ram Park, Yong-Oon Ahn, Tae Min Kim, et al.
Molecular Cancer Therapeutics|December 13, 2019
Clinical Application of Next-Generation Sequencing-Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic StrategiesChanghee Park, Miso Kim, Min Jung Kim, et al.
Journal of Biomedical Nanotechnology|August 25, 2015
Functionalized Polyacrylonitrile Nanofibrous Membranes for Covalent Immobilization of Glucose OxidaseJames Manuel, Miso Kim, Rohini Dharela, et al.
The Korean Journal of Internal Medicine|September 3, 2020
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancerChang Hyun Nam, Jaemoon Koh, Chan-Young Ock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell InfiltrationChan-Young Ock, Bhumsuk Keam, Sehui Kim, et al.
Frontiers in Oncology|June 18, 2024
Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access programSe Hoon Park, Sang Joon Shin, Sun Young Rha, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2024
A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)Yu Jung Kim, Soyeon Kim, Tae Min Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2021
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR<sup>T790M</sup>-Mutant NSCLCHa-Ram Park, Tae Min Kim, Yusoo Lee, et al.
Cancer Research and Treatment|January 8, 2024
Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non-Small Cell Lung CancerHanbaek Yi, Jeonghwan Youk, Yoojoo Lim, et al.
Annals of Hematology|October 11, 2014
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)Miso Kim, Tae Min Kim, Ki Hwan Kim, et al.
Pageof 19

Showing results (101-110 of 184) with videos related to

Sort By:
Pageof 19
Cytotherapy|April 24, 2019
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitorsHa-Ram Park, Yong-Oon Ahn, Tae Min Kim, et al.
Molecular Cancer Therapeutics|December 13, 2019
Clinical Application of Next-Generation Sequencing-Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic StrategiesChanghee Park, Miso Kim, Min Jung Kim, et al.
Journal of Biomedical Nanotechnology|August 25, 2015
Functionalized Polyacrylonitrile Nanofibrous Membranes for Covalent Immobilization of Glucose OxidaseJames Manuel, Miso Kim, Rohini Dharela, et al.
The Korean Journal of Internal Medicine|September 3, 2020
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancerChang Hyun Nam, Jaemoon Koh, Chan-Young Ock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell InfiltrationChan-Young Ock, Bhumsuk Keam, Sehui Kim, et al.
Frontiers in Oncology|June 18, 2024
Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access programSe Hoon Park, Sang Joon Shin, Sun Young Rha, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2024
A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)Yu Jung Kim, Soyeon Kim, Tae Min Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2021
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR<sup>T790M</sup>-Mutant NSCLCHa-Ram Park, Tae Min Kim, Yusoo Lee, et al.
Cancer Research and Treatment|January 8, 2024
Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non-Small Cell Lung CancerHanbaek Yi, Jeonghwan Youk, Yoojoo Lim, et al.
Annals of Hematology|October 11, 2014
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)Miso Kim, Tae Min Kim, Ki Hwan Kim, et al.
Pageof 19